One open atlas of how tumours escape every drug
Knowledge about how cancers become resistant is scattered across thousands of papers and company files. Pooling it into one structured, public resource would let anyone see the pattern.
A curated atlas keyed by drug, target, tumour type and prior therapy, recording observed resistance mechanisms with frequencies, sample sizes and evidence grade, populated from published series, trial correlative data and, ideally, industry-contributed data under a common schema. Analogous resources transformed infectious disease (antimicrobial resistance surveillance) and pharmacogenomics.
- Acquired resistance to every therapy · Nearly every targeted therapy stops working within months to a few years as the tumour adapts.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
- Data silos · Records, scans, genomes and outcomes sit in separate systems that cannot talk. Every patient's experience is lost to the next.
Pages like this
not linked directly; found by shared links- IdeaFund a biopsy at progression, every time, as standard care
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy.
- IdeaTreat resistance like an infectious disease and run national surveillance
Shares Drug resistance (primary and acquired), Data silos, Acquired resistance to every therapy.
- IdeaCut off the emergency programme cancer cells use to survive treatment
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaDrop mandatory fresh biopsies where blood or archival tissue would do
- IdeaA global federated real-world evidence network at regulatory grade
Shares Foundation Medicine (Roche), Data silos.
- IdeaBlock the chemical switch that lets cells hide from treatment
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaTurn off the error-prone repair that manufactures resistance mutations
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
- IdeaMake post-progression sampling a condition of accelerated approval
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.